Cargando…
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors
INTRODUCTION: Aromatase inhibitor-associated arthralgia (AIAA) is a common and often debilitating symptom in breast cancer survivors. Since joint symptoms have been related to estrogen deprivation through the menopausal transition, we hypothesized that genetic polymorphisms in CYP19A1, the final enz...
Autores principales: | Mao, Jun J, Su, H Irene, Feng, Rui, Donelson, Michelle L, Aplenc, Richard, Rebbeck, Timothy R, Stanczyk, Frank, DeMichele, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109575/ https://www.ncbi.nlm.nih.gov/pubmed/21251330 http://dx.doi.org/10.1186/bcr2813 |
Ejemplares similares
-
Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
por: Romero, Sally A.D., et al.
Publicado: (2019) -
Management of arthralgias associated with aromatase inhibitor therapy
por: Thorne, C.
Publicado: (2007) -
Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?
por: Bauml, Joshua, et al.
Publicado: (2015) -
Management of aromatase inhibitor–induced arthralgia
por: Younus, J., et al.
Publicado: (2010) -
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
por: Chim, Kannie, et al.
Publicado: (2013)